Provided by Tiger Trade Technology Pte. Ltd.

Roundhill GLP-1 & Weight Loss ETF

29.60
+0.31121.06%
Post-market: 29.660.0591+0.20%19:30 EDT
Volume:5K
Turnover:139.63K
Market Cap:55.35M
PE:- -
High:29.66
Open:29.08
Low:29.08
Close:29.29
52wk High:37.15
52wk Low:27.34
Shares:1.87M
Float Shares:1.87M
Volume Ratio:0.44
T/O Rate:0.25%
Dividend:0.41
Dividend Rate:1.39%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Novo Nordisk A/S Series B Stock Falls Monday, Underperforms Market

Dow Jones
·
Oct 06

Lilly Expands Oncology Footprint with FDA Win for Pancreatic Cancer Drug

Dow Jones
·
Oct 05

Eli Lilly treatment of pancreatic cancer granted orphan designation

TIPRANKS
·
Oct 05

TRex Bio Files for Nasdaq IPO

MT Newswires Live
·
Oct 05

Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins

THOMSON REUTERS
·
Oct 05

J.P. Morgan Sticks to Their Hold Rating for Novo Nordisk (0QIU)

TIPRANKS
·
Oct 05

Analysts Conflicted on These Healthcare Names: Pfizer (PFE) and Genmab (GMAB)

TIPRANKS
·
Oct 05

Eli Lilly Presents New Ebglyss Data from Phase 3 ADorable-1 Pediatric Atopic Dermatitis Study at Fall Clinical 2026

Reuters
·
Oct 05

Novo Nordisk Could Raise Guidance Alongside Strong Results

Dow Jones
·
Oct 05

Pfizer (PFE) Quietly Builds New Cancer And RSV Powerhouse

TIPRANKS
·
Oct 03

Viking Therapeutics Slides As Cash Raise Spooks Wall Street

TIPRANKS
·
Oct 03

Weight Loss Maintenance Data Could Be A Big Test For Viking Therapeutics Stock (VKTX)

Simply Wall St.
·
Oct 03

Pfizer (PFE) Receives a Hold from Leerink Partners

TIPRANKS
·
Oct 03

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

TIPRANKS
·
Oct 03

Novo Nordisk Says FDA Review of Hemophilia Drug is Hitting Delays

Dow Jones
·
Oct 03

NYSE Most Active Issues

Dow Jones
·
Oct 03

Former Eli Lilly Exec Sells Wyoming Estate for Close to $39.5 Million

Dow Jones
·
Oct 03

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
Oct 03

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
Oct 03

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
Oct 03